Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 5/20 | 0.32 |
| ▸ | ACHE | P22303 | 5/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.32 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.32 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.32 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | FABP1 | P07148 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2921118 | 0.72 | ACHE (0.46) | KDM4EGPR3BCHEACHEALDH1A1 | |
| SCHEMBL8088682 | 0.72 | ACHE (0.46) | KDM4EGPR3BCHEACHEALDH1A1 | |
| SCHEMBL29374271 | 0.72 | ACHE (0.46) | KDM4EGPR3BCHEACHEALDH1A1 | |
| SCHEMBL15647796 | 0.70 | ATM (0.40) | KDM4EGPR3BCHEACHEALDH1A1 | |
| SCHEMBL637592 | 0.68 | KDM4E (0.40) | KDM4EGPR3BCHEACHEALDH1A1 | |
| SCHEMBL18576434 | 0.67 | KDM4E (0.47) | KDM4EGPR3BCHEACHEALDH1A1 | |
| SCHEMBL10377744 | 0.67 | KDM4E (0.39) | KDM4EGPR3BCHEACHEALDH1A1 | |
| SCHEMBL726973 | 0.67 | KDM4E (0.39) | KDM4EGPR3TDP1NPC1 | |
| SCHEMBL6434380 | 0.67 | MAPT (0.46) | KDM4EGPR3ALDH1A1TSHRHSD17B10 | |
| SCHEMBL8274129 | 0.66 | KDM4E (0.41) | KDM4EGPR3ACHEALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 775 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3424926-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINS, THEIR PRODUCTION AND UTILISATION AS MEDICINE | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2019-01-09 | — | — | EP | claimed |
| JP-4832758-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| US-8034941-B2 | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-11 | — | — | US | claimed |
| EP-2308878-A2 | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and use as medicaments | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-04-13 | — | — | EP | claimed |
| EP-2228375-A1 | New xanthin derivatives, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2010-09-15 | — | — | EP | claimed |
| US-20100144703-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-10 | — | — | US | claimed |
| EP-1562946-B1 | NOVEL XANTHINE DERIVATIVES, THE PRODUCTION AND THE USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM PHARMA (DE) | 2010-05-26 | — | — | EP | claimed |
| US-20090258856-A1 | IMIDAZOPYRIDAZINONE AND IMIDAZOPYRIDONE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | US | claimed |
| US-7566707-B2 | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-28 | — | — | US | claimed |
| EP-2060573-A2 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-05-20 | — | — | EP | claimed |
| EP-2058311-A2 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-05-13 | — | — | EP | claimed |
| US-7482337-B2 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-01-27 | — | — | US | claimed |
| US-20080255159-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2008-10-16 | — | — | US | claimed |
| EP-1641799-B1 | IMIDAZO-PYRIDAZINONE DERIVATIVES AND IMIDAZO-PYRIDONE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2008-03-12 | — | — | EP | claimed |
| EP-1562946-A1 | NOVEL XANTHINE DERIVATIVES, THE PRODUCTION AND THE USE THEREOF IN THE FORM OF DRUGS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2005-08-17 | — | — | EP | claimed |
| US-20050026921-A1 | New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-03 | — | — | US | claimed |
| US-20040138214-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | US | claimed |
| WO-2004041820-A1 | NOVEL XANTHINE DERIVATIVES, THE PRODUCTION AND THE USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-21 | — | — | WO | claimed |
| US-20040097510-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-20 | — | — | US | claimed |
| WO-2024150815-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | 田辺三菱製薬株式会社 | 2024-07-18 | — | — | WO | disclosed |
| EP-3632441-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118344346-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-16 | — | — | CN | disclosed |
| EP-3782986-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-10 | — | — | EP | disclosed |
| CN-118290408-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-05 | — | — | CN | disclosed |
| US-20240217957-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-07-04 | — | — | US | disclosed |
| CN-118271297-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-02 | — | — | CN | disclosed |
| CN-118271298-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-02 | — | — | CN | disclosed |
| US-12024505-B2 | Heterocyclic compounds useful as modulators of acetylcholine receptors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-07-02 | — | — | US | disclosed |
| WO-2024135652-A1 | REISSERT-HENZE REACTION USING PHOSPHONIC ACID ANHYDRIDE AS ACTIVATOR | ＡＧＣ株式会社 | 2024-06-27 | — | — | WO | disclosed |
| US-20240199553-A1 | DIFLUOROMETHYLATION REACTION OF HETEROCYCLIC RING USING TETRAFLUOROETHYLENE | AGC Inc. (JP) | 2024-06-20 | — | — | US | disclosed |
| EP-4385977-A1 | DIFLUOROMETHYLATION REACTION OF HETEROCYCLIC RING USING TETRAFLUOROETHYLENE | AGC INC. (JP) | 2024-06-19 | — | — | EP | disclosed |
| US-12012419-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-18 | — | — | US | disclosed |
| WO-2024116086-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-06 | — | — | WO | disclosed |
| US-20240182474-A1 | SUBSTITUTED IMIDAZO [1,2-b] PYRIDAZINES AND [1, 2, 4] TRIAZOLO [ 4,3-b] PYRIDAZINES AS CAMKII INHIBITORS | CARDURION PHARMACEUTICALS, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20240174610-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-30 | — | — | US | disclosed |
| US-20240174677-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-30 | — | — | US | disclosed |
| EP-4034257-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-22 | — | — | EP | disclosed |
| US-11986480-B2 | Heterocyclic compound | TOHOKU UNIVERSITY (JP) | 2024-05-21 | — | — | US | disclosed |
| US-11987586-B1 | Pyrrolo[1,2-c]imidazole derivatives as orexin type 2 receptor agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-21 | — | — | US | disclosed |
| EP-3661923-B1 | N-HETEROCYCLIC COMPOUNDS AS OREXIN 2 AGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-15 | — | — | EP | disclosed |
| WO-2024095133-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-10 | — | — | WO | disclosed |
| CN-118005619-A | Process for producing heterocyclic compound | 武田药品工业株式会社 | 2024-05-10 | — | — | CN | disclosed |
| US-11970483-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-30 | — | — | US | disclosed |
| CN-110799190-B | Heterocyclic compounds | 卡都瑞恩医药有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-112313327-B | Proliferation inhibitors | 千纸鹤治疗公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4351553-A1 | NOVEL ANTI-FIBROTIC DRUGS | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH (DE) | 2024-04-17 | — | — | EP | disclosed |
| US-11958845-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-16 | — | — | US | disclosed |
| CN-117897377-A | Difluoromethylation of heterocycles using tetrafluoroethylene | ＡＧＣ株式会社 | 2024-04-16 | — | — | CN | disclosed |
| US-11952344-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-09 | — | — | US | disclosed |
| US-20240109874-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-04-04 | — | — | US | disclosed |
| US-11939327-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-26 | — | — | US | disclosed |
| US-20240092784-A1 | CONDENSED HETEROCYCLIC COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2024-03-21 | — | — | US | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| CN-113395993-B | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-02-20 | — | — | CN | disclosed |
| WO-2024033845-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-15 | — | — | WO | disclosed |
| CN-117447464-A | Method for producing optically active compound | 首日生物制药公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-114846012-B | 2-isoindole-1, 3, 4-oxadiazole derivatives useful as HDAC6 inhibitors | 武田药品工业株式会社 | 2024-01-26 | — | — | CN | disclosed |
| CN-110753689-B | Process for producing heterocyclic compound | 武田药品工业株式会社 | 2024-01-26 | — | — | CN | disclosed |
| EP-3660003-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-112752760-B | Heterocyclic compounds | 武田药品工业株式会社 | 2024-01-19 | — | — | CN | disclosed |
| WO-2024014512-A1 | LYOPHILIZED COMPOSITION OF NUCLEIC-ACID-LOADED LIPID NANOPARTICLES | 日油株式会社 | 2024-01-18 | — | — | WO | disclosed |
| CN-111918863-B | Heterocyclic compounds | 武田药品工业株式会社 | 2024-01-05 | — | — | CN | disclosed |
| EP-4294447-A1 | POLYSACCHARIDE COMPLEX | Acaryon GmbH (DE) | 2023-12-27 | — | — | EP | disclosed |
| US-11851449-B2 | Heterocyclic amide compounds having an RORvt inhibitory action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-26 | — | — | US | disclosed |
| EP-3693360-B1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-13 | — | — | EP | disclosed |
| US-20230390265-A1 | IRAK4 Inhibitors and Topical Uses Thereof | DERMIRA, INC. | 2023-12-07 | — | — | US | disclosed |
| EP-3693368-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-06 | — | — | EP | disclosed |
| US-11834409-B2 | Heterocyclic NMDA antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-05 | — | — | US | disclosed |
| CN-117157100-A | Polysaccharide complexes | 阿卡扬股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2023227601-A1 | NEAR-INFRARED FLUORESCENT HEPTAMETHINE DYE CONJUGATES WITH FAVORABLE BLEACHING PROPERTIES | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2023-11-30 | — | — | WO | disclosed |
| US-11827601-B2 | Heterocyclic NMDA antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-11-28 | — | — | US | disclosed |
| US-20230357220-A1 | 3-((1H-PYRAZOL-4-YL)METHYL)-6′-(PHENYL)-2H-(1,2′-BIPYRIDIN)-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR USE IN A METHOD OF TREATMENT OF E.G. DEPRESSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-11-09 | — | — | US | disclosed |
| EP-3960172-B1 | ANTIFUNGAL COMPOSITION | SEED RES INSTITUTE CO LTD (JP) | 2023-11-08 | — | — | EP | disclosed |
| US-20230348435-A1 | 1-((1H-PYRAZOL-4-YL)METHYL)-3-(PHENYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR THE TREATMENT OF E.G. DEPRESSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-11-02 | — | — | US | disclosed |
| EP-4267193-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | Ludwig-Maximilians-Universität München (DE) | 2023-11-01 | — | — | EP | disclosed |
| CN-111032047-B | Method for producing optically active compound | 多特疗法-1公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116940354-A | Fused heteroaryl compounds and their use as CaMKII inhibitors | 卡都瑞恩医药股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-11795172-B2 | Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors | CARDURION PHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| WO-2023199091-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-19 | — | — | WO | disclosed |
| EP-3816153-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20230312542-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-05 | — | — | US | disclosed |
| EP-3778587-B1 | HETEROCYCLIC COMPOUND | ORIZURU THERAPEUTICS INC (JP) | 2023-10-04 | — | — | EP | disclosed |
| EP-3895707-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-10-04 | — | — | EP | disclosed |
| US-20230303541-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-28 | — | — | US | disclosed |
| US-11753385-B2 | Method for producing kakeromycin and derivatives thereof | OP BIO FACTORY CO., LTD. (JP) | 2023-09-12 | — | — | US | disclosed |
| US-20230278999-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-07 | — | — | US | disclosed |
| EP-3896060-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023145804-A1 | NOVEL B0AT1 INHIBITOR | 田辺三菱製薬株式会社 | 2023-08-03 | — | — | WO | disclosed |
| EP-4219500-A1 | CONDENSED HETEROCYCLIC COMPOUND | Nissan Chemical Corporation (JP) | 2023-08-02 | — | — | EP | disclosed |
| EP-4216948-A1 | FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS | Cardurion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11713311-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-01 | — | — | US | disclosed |
| EP-3643718-B1 | HETEROCYCLIC COMPOUND AND ITS USE AS POSITIVE ALLOSTERIC MODULATOR OF THE CHOLINERGIC MUSCARINIC M1 RECEPTOR. | TAKEDA PHARMACEUTICALS CO (JP) | 2023-07-26 | — | — | EP | disclosed |
| US-11702419-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-07-18 | — | — | US | disclosed |
| EP-3428150-B1 | AROMATIC RING COMPOUND HAVING A CHOLINERGIC MUSCARINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR ACTIVITY | TAKEDA PHARMACEUTICALS CO (JP) | 2023-07-12 | — | — | EP | disclosed |
| CN-111918866-B | Heterocyclic compounds | 千纸鹤治疗公司 | 2023-07-04 | — | — | CN | disclosed |
| WO-2023113038-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | リードファーマ株式会社 | 2023-06-22 | — | — | WO | disclosed |
| US-20230183227-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-15 | — | — | US | disclosed |
| CN-110709401-B | Heterocyclic compounds | 武田药品工业株式会社 | 2023-06-13 | — | — | CN | disclosed |
| EP-3021847-B1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| CN-116171276-A | 3- ((1H-pyrazol-4-yl) methyl) -6'- (phenyl) -2H- [1,2' -bipyridin ] -2-one derivatives and related compounds as GRP139 antagonists in methods of treating E.G. depression | 武田药品工业株式会社 | 2023-05-26 | — | — | CN | disclosed |
| US-11655241-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-23 | — | — | US | disclosed |
| US-20230149560-A1 | LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150934-A1 | HETEROCYCLIC NMDA ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-18 | — | — | US | disclosed |
| CN-116134038-A | IRAK4 inhibitors and topical use thereof | 德米拉公司 | 2023-05-16 | — | — | CN | disclosed |
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | disclosed |
| EP-3018123-B1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-05-10 | — | — | EP | disclosed |
| US-20230134307-A1 | HETEROCYCLIC NMDA ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-04 | — | — | US | disclosed |
| EP-4172163-A1 | IRAK4 INHIBITORS AND TOPICAL USES THEREOF | Dermira, Inc (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20230125380-A1 | Topical Compositions Comprising IRAK4 Inhibitors for Use in Treating Dermatological Conditions Characterised by Inflammation | DERMIRA, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230117295-A1 | NITROGEN CONTAINING HETEROCYCLES AS CDK12 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-04-20 | — | — | US | disclosed |
| CN-115916812-A | GIP receptor agonist peptide compounds and uses thereof | 武田药品工业株式会社 | 2023-04-04 | — | — | CN | disclosed |
| CN-110325543-B | Cyclic dinucleotides as STING (stimulator of interferon genes) agonists | 武田药品工业株式会社 | 2023-03-31 | — | — | CN | disclosed |
| EP-4153581-A1 | 3-((1H-PYRAZOL-4-YL)METHYL)-6'-(PHENYL)-2H-(1,2'-BIPYRIDIN)-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR USE IN A METHOD OF TREATMENT OF E.G. DEPRESSION | Takeda Pharmaceutical Company Limited (JP) | 2023-03-29 | — | — | EP | disclosed |
| EP-4153583-A1 | 1-((1H-PYRAZOL-4-YL)METHYL)-3-(PHENYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR THE TREATMENT OF E.G. DEPRESSION | Takeda Pharmaceutical Company Limited (JP) | 2023-03-29 | — | — | EP | disclosed |
| US-20230063805-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-02 | — | — | US | disclosed |
| US-11584737-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-21 | — | — | US | disclosed |
| WO-2023017798-A1 | DIFLUOROMETHYLATION REACTION OF HETEROCYCLIC RING USING TETRAFLUOROETHYLENE | ＡＧＣ株式会社 | 2023-02-16 | — | — | WO | disclosed |
| US-20230040770-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2023-02-09 | — | — | US | disclosed |
| US-20230042358-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-09 | — | — | US | disclosed |
| US-20230037557-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-09 | — | — | US | disclosed |
| US-20230037538-A1 | ANTI-ALS COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-09 | — | — | US | disclosed |
| EP-4126920-A2 | GIF RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| EP-4129402-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2023-02-08 | — | — | EP | disclosed |
| EP-4126921-A2 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| US-11572384-B2 | Unusual substrates of tubulin tyrosine ligase | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2023-02-07 | — | — | US | disclosed |
| CN-109195599-B | Antifungal composition | 株式会社种探索研究所 | 2023-02-03 | — | — | CN | disclosed |
| US-11560372-B2 | Heterocyclic compounds useful as modulators of acetylcholine receptors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-24 | — | — | US | disclosed |
| US-20230002318-A1 | HETEROCYCLIC NMDA ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-05 | — | — | US | disclosed |
| US-20220411413-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-12-29 | — | — | US | disclosed |
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-29 | — | — | US | disclosed |
| EP-3663281-B1 | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2022-12-28 | — | — | EP | disclosed |
| US-20220402935-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2022-12-22 | — | — | US | disclosed |
| WO-2022258792-A1 | NOVEL ANTI-FIBROTIC DRUGS | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2022-12-15 | — | — | WO | disclosed |
| US-20220388995-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-08 | — | — | US | disclosed |
| US-11518763-B2 | Macrocyclic compound and use thereof | SCOHIA PHARMA, INC. (JP) | 2022-12-06 | — | — | US | disclosed |
| CN-115335395-A | QD administration of GIP receptor agonist peptide compounds and uses thereof | 武田药品工业株式会社 | 2022-11-11 | — | — | CN | disclosed |
| CN-115298173-A | Hydroxypyrrolidine derivatives and medical use thereof | 田边三菱制药株式会社 | 2022-11-04 | — | — | CN | disclosed |
| CN-115197160-A | Heterocyclic compounds | 武田药品工业株式会社 | 2022-10-18 | — | — | CN | disclosed |
| CN-115160248-A | Method for producing Kakeromycin and derivatives thereof | 海洋规划生物工厂株式会社 | 2022-10-11 | — | — | CN | disclosed |
| EP-4066893-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2022-10-05 | — | — | EP | disclosed |
| WO-2022186098-A1 | STABLE NOVEL AROMATIC BORONIC ACID ESTER | 国立大学法人大阪大学 | 2022-09-09 | — | — | WO | disclosed |
| CN-110573512-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-09-06 | — | — | CN | disclosed |
| CN-111051295-B | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |
| CN-115003670-A | Heterocyclic compounds | 武田药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |
| WO-2022175390-A1 | POLYSACCHARIDE COMPLEX | ACARYON GMBH (DE) | 2022-08-25 | — | — | WO | disclosed |
| CN-114929223-A | Topical composition comprising an IRAK4 inhibitor for the treatment of skin conditions characterized by inflammation | 德米拉公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-114874131-A | Method for producing Kakeromycin and derivatives thereof | 海洋规划生物工厂株式会社 | 2022-08-09 | — | — | CN | disclosed |
| CN-111148746-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-08-05 | — | — | CN | disclosed |
| EP-4034536-A1 | 2-ISOINDOL-1,3,4-OXADIAZOLE DERIVATIVES USEFUL AS HDAC6 INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2022-08-03 | — | — | EP | disclosed |
| CN-114835596-A | Method for producing Kakeromycin and derivatives thereof | 海洋规划生物工厂株式会社 | 2022-08-02 | — | — | CN | disclosed |
| CN-114846012-A | 2-isoindole-1, 3, 4-oxadiazole derivatives useful as HDAC6 inhibitors | 武田药品工业株式会社 | 2022-08-02 | — | — | CN | disclosed |
| US-20220227830-A1 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-07-21 | — | — | US | disclosed |
| EP-3612527-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | TAKEDA PHARMACEUTICALS CO (JP) | 2022-07-20 | — | — | EP | disclosed |
| CN-110461828-B | IP6K inhibitors | 武田药品工业株式会社 | 2022-07-19 | — | — | CN | disclosed |
| US-11390634-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-07-19 | — | — | US | disclosed |
| CN-114728900-A | Heterocyclic NMDA antagonists | 武田药品工业株式会社 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022136555-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-30 | — | — | WO | disclosed |
| CN-109790122-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-06-24 | — | — | CN | disclosed |
| US-20220193251-A1 | CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-23 | — | — | US | disclosed |
| WO-2022129210-A2 | INHIBITION OF VIRUS PROTEASE | HELMHOLTZ ZENTRUM MUENCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2022-06-23 | — | — | WO | disclosed |
| CN-107108506-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-06-21 | — | — | CN | disclosed |
| EP-4005637-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2022-06-01 | — | — | EP | disclosed |
| EP-4005638-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2022-06-01 | — | — | EP | disclosed |
| EP-4006037-A1 | HETEROCYCLIC COMPOUND | Fimecs, Inc. (JP) | 2022-06-01 | — | — | EP | disclosed |
| CN-107709335-B | Method for producing Kakeromycin and derivatives thereof | 海洋规划生物工厂株式会社 | 2022-05-31 | — | — | CN | disclosed |
| EP-4001275-A1 | (S)-ENANTIOMER OF MEPAZINE AS PARACASPASE (MALT1) INHIBITOR FOR THE TREATMENT OF CANCER | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH (DE) | 2022-05-25 | — | — | EP | disclosed |
| EP-3514149-B1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-05-18 | — | — | EP | disclosed |
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-05-05 | — | — | US | disclosed |
| EP-3604452-B1 | GEL HAVING MUTUALLY INTRUSIVE NETWORK STRUCTURES | SUMITOMO CHEMICAL CO (JP) | 2022-05-04 | — | — | EP | disclosed |
| US-11319286-B2 | Heterocyclic compound and application thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-05-03 | — | — | US | disclosed |
| CN-110582499-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-04-29 | — | — | CN | disclosed |
| CN-109477094-B | Peptide compounds | 武田药品工业株式会社 | 2022-04-26 | — | — | CN | disclosed |
| US-20220119391-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2022-04-21 | — | — | US | disclosed |
| EP-3984994-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2022-04-20 | — | — | EP | disclosed |
| US-20220098180-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-31 | — | — | US | disclosed |
| US-RE48992-E1 | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MÜNCHEN-DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2022-03-29 | — | — | US | disclosed |
| US-20220089525-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-24 | — | — | US | disclosed |
| CN-114181136-A | Substituted piperidine compounds and uses thereof | 武田药品工业株式会社 | 2022-03-15 | — | — | CN | disclosed |
| US-11274101-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| CN-114173824-A | Antibody drug conjugates | 武田药品工业株式会社 | 2022-03-11 | — | — | CN | disclosed |
| US-20220040318-A1 | PRIMARY AMINE COMPOUND OR SECONDARY AMINE COMPOUND-ACIDIC POLYSACCHARIDE CONJUGATE AND PRODUCTION METHOD THEREFOR | SEIKAGAKU CORPORATION (JP) | 2022-02-10 | — | — | US | disclosed |
| US-11242348-B2 | — | — | 2022-02-08 | — | — | US | disclosed |
| US-11236099-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-01 | — | — | US | disclosed |
| US-20220024883-A1 | METHOD FOR PRODUCING KAKEROMYCIN AND DERIVATIVES THEREOF | OP BIO FACTORY CO., LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
| US-11230541-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-25 | — | — | US | disclosed |
| US-20220017530-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-20 | — | — | US | disclosed |
| US-20220017514-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-20 | — | — | US | disclosed |
| US-20220016215-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-20 | — | — | US | disclosed |
| CN-109415384-B | Fused heterocyclic compound | 武田药品工业株式会社 | 2022-01-11 | — | — | CN | disclosed |
| WO-2022006129-A1 | IRAK4 INHIBITORS AND TOPICAL USES THEREOF | DERMIRA, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| EP-3013818-B1 | (S)-ENANTIOMER OF MEPAZINE AS PARACASPASE (MALT1) INHIBITOR FOR TREATING CANCER | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2021-12-29 | — | — | EP | disclosed |
| US-11197858-B2 | Substituted amines for treating cardiac diseases | CARDURION PHARMACEUTICALS, LLC (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210380565-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-12-09 | — | — | US | disclosed |
| EP-3919055-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-12-08 | — | — | EP | disclosed |
| EP-3915638-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2021-12-01 | — | — | EP | disclosed |
| US-11186565-B2 | Aromatic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-30 | — | — | US | disclosed |
| US-11185548-B2 | Inhibitors of cytochrome P450 family 7 subfamily B member 1 (CYP7B1) for use in treating diseases | HELMHOLTZ ZENTRUM MUNCHEN—DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2021-11-30 | — | — | US | disclosed |
| CN-108884043-B | Substituted piperidine compounds and uses thereof | 武田药品工业株式会社 | 2021-11-26 | — | — | CN | disclosed |
| US-20210363130-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-25 | — | — | US | disclosed |
| WO-2021234450-A1 | 1-((1H-PYRAZOL-4-YL)METHYL)-3-(PHENYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR THE TREATMENT OF E.G. DEPRESSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021234451-A1 | 3-((1H-PYRAZOL-4-YL)METHYL)-6'-(PHENYL)-2H-(1,2'-BIPYRIDIN)-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR USE IN A METHOD OF TREATMENT OF E.G. DEPRESSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-25 | — | — | WO | disclosed |
| US-20210353686-A1 | INSULIN-PRODUCING CELLS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-18 | — | — | US | disclosed |
| US-11174301-B2 | Peptide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-16 | — | — | US | disclosed |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-20210347786-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-11 | — | — | US | disclosed |
| US-20210340114-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-04 | — | — | US | disclosed |
| US-20210332053-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-28 | — | — | US | disclosed |
| WO-2021216572-A1 | LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-3464260-B1 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | UNIV MUENCHEN TECH (DE) | 2021-10-27 | — | — | EP | disclosed |
| US-11155526-B2 | Method for producing kakeromycin and derivatives thereof | OP BIO FACTORY CO., LTD. (JP) | 2021-10-26 | — | — | US | disclosed |
| EP-3896060-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-10-20 | — | — | EP | disclosed |
| EP-3895707-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-10-20 | — | — | EP | disclosed |
| EP-3890738-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | Scohia Pharma, Inc. (JP) | 2021-10-13 | — | — | EP | disclosed |
| WO-2021193984-A2 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021193983-A2 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-30 | — | — | WO | disclosed |
| US-20210290629-A1 | ACC INHIBITORS FOR USE IN TREATING MYCOBACTERIAL DISEASES | FORSCHUNGSZENTRUM BORSTEL LEIBNIZ-ZENTRUM FUER MEDIZIN UND BIOWISSENSCHAFTEN (DE) | 2021-09-23 | — | — | US | disclosed |
| US-20210292308-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-23 | — | — | US | disclosed |
| CN-113395993-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2021-09-14 | — | — | CN | disclosed |
| US-20210277030-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-09 | — | — | US | disclosed |
| US-20210276949-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-09 | — | — | US | disclosed |
| CN-110494499-B | Gel with interpenetrating network structure | 住友化学株式会社 | 2021-08-31 | — | — | CN | disclosed |
| US-20210254014-A1 | GROWTH INHIBITOR | KYOTO UNIVERSITY (JP) | 2021-08-19 | — | — | US | disclosed |
| EP-3594202-B1 | SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2021-08-11 | — | — | EP | disclosed |
| EP-3594203-B1 | SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858838-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858823-A1 | CONDENSED-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858828-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-08-04 | — | — | EP | disclosed |
| EP-3856339-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2021-08-04 | — | — | EP | disclosed |
| EP-3856768-A2 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2021-08-04 | — | — | EP | disclosed |
| CN-109715613-B | Heterocyclic compounds | 武田药品工业株式会社 | 2021-07-30 | — | — | CN | disclosed |
| EP-3854869-A1 | INSULIN-PRODUCING CELLS | Takeda Pharmaceutical Company Limited (JP) | 2021-07-28 | — | — | EP | disclosed |
| US-11066374-B2 | Method for producing kakeromycin and derivatives thereof | OP BIO FACTORY CO., LTD. (JP) | 2021-07-20 | — | — | US | disclosed |
| EP-3848353-A1 | MEDICAMENTS FOR THE TREATMENT OF OPHTHALMIC DISEASES | Takeda Pharmaceutical Company Limited (JP) | 2021-07-14 | — | — | EP | disclosed |
| US-11059780-B2 | Substituted pyrrolidine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-07-13 | — | — | US | disclosed |
| US-11053262-B2 | Heterocyclic amide compounds having RORyT inhibitory action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-07-06 | — | — | US | disclosed |
| US-20210198240-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-07-01 | — | — | US | disclosed |
| CN-107365321-B | Oxaaziridine compounds and process for their preparation | 株式会社种探索研究所 | 2021-06-29 | — | — | CN | disclosed |
| US-20210179603-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2021-06-17 | — | — | US | disclosed |
| US-11034700-B2 | Substituted pyrrolidine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-15 | — | — | US | disclosed |
| EP-3287441-B1 | ACYLATED 4-AMINOPIPERIDINES AS INHIBITORS OF SERINE PALMITOYLTRANSFERASE | TAKEDA PHARMACEUTICALS CO (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-11028048-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-08 | — | — | US | disclosed |
| WO-2021106975-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2021-06-03 | — | — | WO | disclosed |
| WO-2021094832-A1 | HETEROCYCLIC NMDA ANTAGONISTS | TAKEDA PHARAMACEUTICAL COMPANY LIMITED (JP) | 2021-05-20 | — | — | WO | disclosed |
| US-20210139491-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-05-13 | — | — | US | disclosed |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-05-13 | — | — | US | disclosed |
| EP-3816154-A1 | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2021-05-05 | — | — | EP | disclosed |
| EP-3816153-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2021-05-05 | — | — | EP | disclosed |
| CN-112752760-A | Heterocyclic compounds | 武田药品工业株式会社 | 2021-05-04 | — | — | CN | disclosed |
| EP-3812456-A1 | GROWTH INHIBITOR | Kyoto University (JP) | 2021-04-28 | — | — | EP | disclosed |
| US-10988469-B2 | Method for producing optically active compound | DOT THERAPEUTICS-1, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20210115048-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-22 | — | — | US | disclosed |
| WO-2021075476-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2021-04-22 | — | — | WO | disclosed |
| US-20210115067-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-22 | — | — | US | disclosed |
| US-10980813-B2 | Antifungal composition | SEED RESEARCH INSTITUTE CO., LTD. (JP) | 2021-04-20 | — | — | US | disclosed |
| US-10981934-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-20 | — | — | US | disclosed |
| US-10980825-B2 | Cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-20 | — | — | US | disclosed |
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-15 | — | — | US | disclosed |
| US-10975043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-13 | — | — | US | disclosed |
| CN-106573877-B | Cationic lipids | 武田药品工业株式会社 | 2021-04-13 | — | — | CN | disclosed |
| US-10968213-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-06 | — | — | US | disclosed |
| US-10968178-B2 | IP6K inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-06 | — | — | US | disclosed |
| US-10968231-B2 | Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders | SCOHIA PHARMA, INC. (JP) | 2021-04-06 | — | — | US | disclosed |
| US-20210094944-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | US | disclosed |
| WO-2021059017-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021060567-A1 | 2-ISOINDOL-1,3,4-OXADIAZOLE DERIVATIVES USEFUL AS HDAC6 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | WO | disclosed |
| CN-107848971-B | Heterocyclic compounds | 武田药品工业株式会社 | 2021-03-26 | — | — | CN | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3366679-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2021-03-24 | — | — | EP | disclosed |
| CN-105611930-B | Spiro quinoxaline derivatives as non-apoptotic regulated cell death inhibitors | 亥姆霍兹慕尼黑中心-德国环境与健康研究中心（股份有限公司） | 2021-03-02 | — | — | CN | disclosed |
| EP-3782986-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-02-24 | — | — | EP | disclosed |
| EP-3774800-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778587-A1 | HETEROCYCLIC COMPOUND | Kyoto University (JP) | 2021-02-17 | — | — | EP | disclosed |
| EP-3512861-B1 | CYCLIC DINUCLEOTIDES AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-02-17 | — | — | EP | disclosed |
| US-10919891-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-02-16 | — | — | US | disclosed |
| CN-108431004-B | Heterocyclic compounds | 武田药品工业株式会社 | 2021-02-12 | — | — | CN | disclosed |
| CN-108026088-B | Oxadiazole derivatives as HDAC inhibitors | 武田药品工业株式会社 | 2021-02-12 | — | — | CN | disclosed |
| WO-2021020585-A1 | HETEROCYCLIC COMPOUND | ファイメクス株式会社 | 2021-02-04 | — | — | WO | disclosed |
| WO-2021020362-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2021-02-04 | — | — | WO | disclosed |
| WO-2021020363-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2021-02-04 | — | — | WO | disclosed |
| CN-112313327-A | Proliferation inhibitor | 国立大学法人京都大学 | 2021-02-02 | — | — | CN | disclosed |
| US-20210024512-A1 | HETEROCYCLIC COMPOUND | KYOTO UNIVERSITY (JP) | 2021-01-28 | — | — | US | disclosed |
| US-10899752-B2 | 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-01-26 | — | — | US | disclosed |
| US-10898737-B2 | Substituted piperidine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-01-26 | — | — | US | disclosed |
| US-20210015933-A1 | BIOACTIVE CARBOXYLIC ACID TYPE COMPOUND-POLYMER CONJUGATE, AND METHOD FOR MANUFACTURING THE SAME | SEIKAGAKU CORPORATION (JP) | 2021-01-21 | — | — | US | disclosed |
| US-20210009572-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2021-01-14 | — | — | US | disclosed |
| US-20210009550-A1 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | Technische Universität München (DE) | 2021-01-14 | — | — | US | disclosed |
| US-20200407515-A1 | GEL HAVING INTERPENETRATING NETWORK | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2020-12-31 | — | — | US | disclosed |
| EP-3133075-B1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-12-30 | — | — | EP | disclosed |
| US-10875862-B2 | — | — | 2020-12-29 | — | — | US | disclosed |
| US-20200392149-A1 | SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-17 | — | — | US | disclosed |
| US-10865200-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-15 | — | — | US | disclosed |
| CN-108368127-B | Compounds and their use as EP4 receptor antagonists | 武田药品工业株式会社 | 2020-12-11 | — | — | CN | disclosed |
| US-20200385346-A1 | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-10 | — | — | US | disclosed |
| US-20200385345-A1 | SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-10 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
| US-20200377509-A1 | SUBSTITUTED CYCLYL-ACETIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-03 | — | — | US | disclosed |
| US-20200377458-A1 | IP6K INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-03 | — | — | US | disclosed |
| EP-3210973-B1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF OPHTHALMIC DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-12-02 | — | — | EP | disclosed |
| WO-2020229982-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-11-19 | — | — | WO | disclosed |
| CN-111936495-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2020-11-13 | — | — | CN | disclosed |
| EP-3313836-B1 | 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR | TAKEDA PHARMACEUTICALS CO (JP) | 2020-11-11 | — | — | EP | disclosed |
| CN-111918863-A | Heterocyclic compounds | 武田药品工业株式会社 | 2020-11-10 | — | — | CN | disclosed |
| CN-111918866-A | Heterocyclic compounds | 国立大学法人京都大学 | 2020-11-10 | — | — | CN | disclosed |
| US-20200339577-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-29 | — | — | US | disclosed |
| US-10807987-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-20 | — | — | US | disclosed |
| US-10800754-B2 | Heterocyclic amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-13 | — | — | US | disclosed |
| US-20200317659-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| WO-2020196828-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2020-10-01 | — | — | WO | disclosed |
| US-10787462-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-09-29 | — | — | US | disclosed |
| US-10774083-B2 | Heterocyclic amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-09-15 | — | — | US | disclosed |
| EP-3366684-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-02 | — | — | EP | disclosed |
| EP-3287454-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-02 | — | — | EP | disclosed |
| EP-3279191-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-02 | — | — | EP | disclosed |
| US-20200270243-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-27 | — | — | US | disclosed |
| US-10745397-B2 | 1-Substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as EP4 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-18 | — | — | US | disclosed |
| US-20200255439-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-13 | — | — | US | disclosed |
| EP-3693368-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-08-12 | — | — | EP | disclosed |
| EP-3693360-A1 | HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2020-08-12 | — | — | EP | disclosed |
| WO-2020158762-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2020-08-06 | — | — | WO | disclosed |
| US-20200247747-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-06 | — | — | US | disclosed |
| US-20200247801-A1 | HETEROCYLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-06 | — | — | US | disclosed |
| EP-3689879-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-08-05 | — | — | EP | disclosed |
| CN-107207444-B | Bicyclic compounds | 武田药品工业株式会社 | 2020-07-24 | — | — | CN | disclosed |
| US-20200230137-A1 | SUBSTITUTED AMINES FOR TREATING CARDIAC DISEASES | CARDURION PHARMACEUTICALS, LLC (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200231579-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-23 | — | — | US | disclosed |
| US-10710989-B2 | Method for producing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-14 | — | — | US | disclosed |
| US-10703732-B2 | Method for producing kakeromycin and derivatives thereof | OP BIO FACTORY CO., LTD. (JP) | 2020-07-07 | — | — | US | disclosed |
| US-20200207734-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-02 | — | — | US | disclosed |
| US-20200207715-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-02 | — | — | US | disclosed |
| US-10696651-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-30 | — | — | US | disclosed |
| WO-2020129900-A1 | METHOD FOR PRODUCING C-ARYLHYDROXY GLYCOXIDE DERIVATIVE | 株式会社トクヤマ | 2020-06-25 | — | — | WO | disclosed |
| WO-2020129901-A1 | METHOD FOR PREPARING KETONE COMPOUND | 株式会社トクヤマ | 2020-06-25 | — | — | WO | disclosed |
| WO-2020129899-A1 | METHOD FOR PRODUCING C-ARYL HYDROXY GLYCOXIDE DERIVATIVES | 株式会社トクヤマ | 2020-06-25 | — | — | WO | disclosed |
| WO-2020122092-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2020-06-18 | — | — | WO | disclosed |
| WO-2020122093-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2020-06-18 | — | — | WO | disclosed |
| WO-2020116660-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2020-06-11 | — | — | WO | disclosed |
| EP-3663281-A1 | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2020-06-10 | — | — | EP | disclosed |
| EP-3661923-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2020-06-10 | — | — | EP | disclosed |
| EP-3661931-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-06-10 | — | — | EP | disclosed |
| EP-3660003-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-06-03 | — | — | EP | disclosed |
| US-20200163970-A1 | HETEROCYCLIC COMPOUND | TOHOKU UNIVERSITY (JP) | 2020-05-28 | — | — | US | disclosed |
| US-20200157062-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-05-21 | — | — | US | disclosed |
| EP-3134386-B1 | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-20 | — | — | EP | disclosed |
| EP-3436444-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-13 | — | — | EP | disclosed |
| CN-111148746-A | Heterocyclic compounds | 武田药品工业株式会社 | 2020-05-12 | — | — | CN | disclosed |
| US-20200138964-A1 | TERTIARY AMINE COMPOUND OR IMINE COMPOUND-POLYMER CONJUGATE AND PRODUCTION METHOD THEREFOR | SEIKAGAKU CORPORATION (JP) | 2020-05-07 | — | — | US | disclosed |
| US-20200140462-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-05-07 | — | — | US | disclosed |
| US-20200140505-A1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2020-05-07 | — | — | US | disclosed |
| US-20200131174-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
| EP-3178807-B1 | CATIONIC LIPID | TAKEDA PHARMACEUTICALS CO (JP) | 2020-04-29 | — | — | EP | disclosed |
| EP-3643718-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-04-29 | — | — | EP | disclosed |
| CN-111051295-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2020-04-21 | — | — | CN | disclosed |
| CN-111032047-A | Process for producing optically active compound | 千年制药公司 | 2020-04-17 | — | — | CN | disclosed |
| US-20200115399-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-16 | — | — | US | disclosed |
| US-10618876-B2 | Method for producing kakeromycin and derivatives thereof | OP BIO FACTORY CO., LTD. (JP) | 2020-04-14 | — | — | US | disclosed |
| EP-3632441-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Millennium Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10610520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-07 | — | — | US | disclosed |
| WO-2020067557-A2 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020067456-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2020-04-02 | — | — | WO | disclosed |
| WO-2020067575-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020067457-A1 | CONDENSED-CYCLIC COMPOUND | 武田薬品工業株式会社 | 2020-04-02 | — | — | WO | disclosed |
| WO-2020067455-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2020-04-02 | — | — | WO | disclosed |
| WO-2020059892-A1 | INSULIN-PRODUCING CELLS | 武田薬品工業株式会社 | 2020-03-26 | — | — | WO | disclosed |
| US-20200085833-A1 | INHIBITORS OF CYTOCHROME P450 FAMILY 7 SUBFAMILY B MEMBER 1 (CYP7B1) FOR USE IN TREATING DISEASES | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2020-03-19 | — | — | US | disclosed |
| EP-3325475-B1 | OXADIAZOLE DERIVATIVES USEFUL AS HDAC INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-18 | — | — | EP | disclosed |
| US-10584097-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-03-10 | — | — | US | disclosed |
| EP-3617209-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-03-04 | — | — | EP | disclosed |
| EP-3617208-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-03-04 | — | — | EP | disclosed |
| US-10577382-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-03-03 | — | — | US | disclosed |
| EP-3612527-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | Takeda Pharmaceutical Company Limited (JP) | 2020-02-26 | — | — | EP | disclosed |
| CN-110799190-A | Heterocyclic compounds | 卡都瑞恩医药有限责任公司 | 2020-02-14 | — | — | CN | disclosed |
| US-20200039957-A1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-06 | — | — | US | disclosed |
| EP-3600327-A1 | HETEROCYCLIC COMPOUND | Cardurion Pharmaceuticals, LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3239150-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-02-05 | — | — | EP | disclosed |
| EP-3601329-A1 | GIP RECEPTOR ACTIVATING PEPTIDE | Takeda Pharmaceutical Company Limited (JP) | 2020-02-05 | — | — | EP | disclosed |
| EP-3604452-A1 | GEL HAVING MUTUALLY INTRUSIVE NETWORK STRUCTURES | Sumitomo Chemical Company, Limited (JP) | 2020-02-05 | — | — | EP | disclosed |
| EP-3601260-A1 | SUBSTITUTED CYCLYL-ACETIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Takeda Pharmaceutical Company Limited (JP) | 2020-02-05 | — | — | EP | disclosed |
| EP-3601256-A1 | IP6K INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2020-02-05 | — | — | EP | disclosed |
| EP-3604267-A1 | AROMATIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-02-05 | — | — | EP | disclosed |
| CN-110753689-A | Process for producing heterocyclic compound | 武田药品工业株式会社 | 2020-02-04 | — | — | CN | disclosed |
| US-10548877-B2 | Aromatic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-04 | — | — | US | disclosed |
| US-10548899-B2 | Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-04 | — | — | US | disclosed |
| US-10543212-B2 | Substituted amines for treating cardiac diseases | CARDURION PHARMACEUTICALS, LLC (US) | 2020-01-28 | — | — | US | disclosed |
| US-10544111-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-01-28 | — | — | US | disclosed |
| CN-110719903-A | Aromatic ring compound | 武田药品工业株式会社 | 2020-01-21 | — | — | CN | disclosed |
| CN-110709401-A | Heterocyclic compounds | 武田药品工业株式会社 | 2020-01-17 | — | — | CN | disclosed |
| CN-110709414-A | GIP receptor activating peptide | 武田药品工业有限公司 | 2020-01-17 | — | — | CN | disclosed |
| US-20200017444-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-01-16 | — | — | US | disclosed |
| CN-110678458-A | Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders | 武田药品工业株式会社 | 2020-01-10 | — | — | CN | disclosed |
| EP-3066094-B1 | PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-08 | — | — | EP | disclosed |
| EP-3325490-B1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2019-12-18 | — | — | EP | disclosed |
| CN-110582499-A | Heterocyclic compounds | 武田药品工业株式会社 | 2019-12-17 | — | — | CN | disclosed |
| CN-110573512-A | Heterocyclic compounds | 武田药品工业株式会社 | 2019-12-13 | — | — | CN | disclosed |
| CN-105209485-B | Peptide compounds | 武田药品工业株式会社 | 2019-12-10 | — | — | CN | disclosed |
| CN-107835800-B | Cyclic compound | 武田药品工业株式会社 | 2019-11-26 | — | — | CN | disclosed |
| US-10472376-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-11-12 | — | — | US | disclosed |
| EP-3275874-B1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-30 | — | — | EP | disclosed |
| EP-3558304-A2 | INHIBITORS OF CYTOCHROME P450 FAMILY 7 SUBFAMILY B MEMBER 1 (CYP7B1) FOR USE IN TREATING DISEASES | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3560516-A1 | COMBINATION THERAPY INCLUDING BETA-SITOSTEROL IN COMBINATION WITH AT LEAST ONE OF A BRAF INHIBITOR, A MEK INHIBITOR OR AN ERK INHIBITOR AND METHODS AND USE THEREOF | Bergen Teknologioverforing AS (NO) | 2019-10-30 | — | — | EP | disclosed |
| US-10457670-B2 | Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-29 | — | — | US | disclosed |
| EP-3205645-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-23 | — | — | EP | disclosed |
| US-20190315735-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-17 | — | — | US | disclosed |
| EP-3210971-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-16 | — | — | EP | disclosed |
| US-20190307760-A1 | ACC INHIBITORS FOR USE IN TREATING MYCOBACTERIAL DISEASES | FORSCHUNGZENTRUM BORSTEL LEIBNIZ-ZENTRUM FÜR MEDIZIN UND BIOWISSENSCHAFTEN (DE) | 2019-10-10 | — | — | US | disclosed |
| US-10435399-B2 | HDAC6 inhibitory heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-08 | — | — | US | disclosed |
| US-10435445-B2 | Peptide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-08 | — | — | US | disclosed |
| WO-2019189945-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-03 | — | — | WO | disclosed |
| US-20190300536-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-03 | — | — | US | disclosed |
| WO-2019189553-A1 | HETEROCYCLIC COMPOUND | 国立大学法人京都大学 | 2019-10-03 | — | — | WO | disclosed |
| WO-2019189555-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2019-10-03 | — | — | WO | disclosed |
| US-10428023-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-01 | — | — | US | disclosed |
| US-10428056-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-01 | — | — | US | disclosed |
| US-10414761-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-17 | — | — | US | disclosed |
| US-10406146-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190263843-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-29 | — | — | US | disclosed |
| US-20190248776-A1 | 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-15 | — | — | US | disclosed |
| US-20190241547-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190241566-A1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| WO-2019151269-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2019-08-08 | — | — | WO | disclosed |
| EP-3156397-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| EP-2907802-B1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| EP-3514149-A1 | HETEROCYCLIC AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-07-24 | — | — | EP | disclosed |
| EP-3514150-A1 | HETEROCYCLIC AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-07-24 | — | — | EP | disclosed |
| EP-3512861-A2 | CYCLIC DINUCLEOTIDES AS STING (STIMULATOR OF INTEFERON GENES) AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2019-07-24 | — | — | EP | disclosed |
| US-10357484-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-23 | — | — | US | disclosed |
| US-20190216820-A1 | ANTIFUNGAL COMPOSITION | SEED RESEARCH INSTITUTE CO., LTD. (JP) | 2019-07-18 | — | — | US | disclosed |
| US-20190202883-A1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-04 | — | — | US | disclosed |
| EP-3239142-B1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-10336864-B2 | Production method for poly(amino acid) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-02 | — | — | US | disclosed |
| US-20190192549-A1 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICALS CO (JP) | 2019-06-27 | — | — | US | disclosed |
| EP-3498693-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-06-19 | — | — | EP | disclosed |
| US-10323026-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-18 | — | — | US | disclosed |
| US-10323027-B2 | 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-18 | — | — | US | disclosed |
| US-20190169166-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-06 | — | — | US | disclosed |
| US-10308643-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| US-10301292-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-28 | — | — | US | disclosed |
| US-20190152929-A1 | METHOD FOR PRODUCING KAKEROMYCIN AND DERIVATIVES THEREOF | OP BIO FACTORY CO., LTD. (JP) | 2019-05-23 | — | — | US | disclosed |
| US-20190144493-A1 | UNUSUAL SUBSTRATES OF TUBULIN TYROSINE LIGASE | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2019-05-16 | — | — | US | disclosed |
| US-10287305-B2 | Substituted piperidine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-14 | — | — | US | disclosed |
| US-20190135799-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
| US-10280179-B2 | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2019-05-07 | — | — | US | disclosed |
| US-20190125728-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-02 | — | — | US | disclosed |
| US-20190119225-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-25 | — | — | US | disclosed |
| US-20190106437-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-11 | — | — | US | disclosed |
| EP-3464260-A2 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | Technische Universität München (DE) | 2019-04-10 | — | — | EP | disclosed |
| EP-3467106-A1 | PEPTIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-10252997-B2 | Monocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-09 | — | — | US | disclosed |
| US-10252974-B2 | Cationic lipid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-09 | — | — | US | disclosed |
| US-20190083467-A1 | AROMATIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-03-21 | — | — | US | disclosed |
| US-10208046-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-19 | — | — | US | disclosed |
| US-10202383-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-02-12 | — | — | US | disclosed |
| US-10202376-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-12 | — | — | US | disclosed |
| US-20190040010-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-07 | — | — | US | disclosed |
| WO-2019027058-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019027054-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-07 | — | — | WO | disclosed |
| EP-3436444-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-02-06 | — | — | EP | disclosed |
| EP-3438109-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-02-06 | — | — | EP | disclosed |
| US-20190031611-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
| US-10189785-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2019-01-29 | — | — | US | disclosed |
| US-20190023667-A1 | METHOD FOR PRODUCING KAKEROMYCIN AND DERIVATIVES THEREOF | OP BIO FACTORY CO., LTD. (JP) | 2019-01-24 | — | — | US | disclosed |
| US-20190023668-A1 | METHOD FOR PRODUCING KAKEROMYCIN AND DERIVATIVES THEREOF | OP BIO FACTORY CO., LTD. (JP) | 2019-01-24 | — | — | US | disclosed |
| US-20190023669-A1 | METHOD FOR PRODUCING KAKEROMYCIN AND DERIVATIVES THEREOF | OP BIO FACTORY CO., LTD. (JP) | 2019-01-24 | — | — | US | disclosed |
| EP-3428150-A1 | AROMATIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-01-16 | — | — | EP | disclosed |
| US-20190008836-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-10 | — | — | US | disclosed |
| EP-3424926-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINS, THEIR PRODUCTION AND UTILISATION AS MEDICINE | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2019-01-09 | — | — | EP | disclosed |
| US-20180362516-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-12-20 | — | — | US | disclosed |
| EP-3411358-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2018-12-12 | — | — | EP | disclosed |
| US-20180346452-A1 | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | TAKEDA PHARMACEUTICALS CO (JP) | 2018-12-06 | — | — | US | disclosed |
| US-10131653-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-11-20 | — | — | US | disclosed |
| US-20180319819-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-11-08 | — | — | US | disclosed |
| US-20180319812-A1 | HETEROCYCLIC COMPOUND | ACTION MEDICAL TECHNOLOGIES, LLC | 2018-11-08 | — | — | US | disclosed |
| WO-2018194181-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-25 | — | — | WO | disclosed |
| US-20180303841-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-25 | — | — | US | disclosed |
| EP-3087067-B1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2018-10-24 | — | — | EP | disclosed |
| US-10106509-B2 | Method for producing kakeromycin and derivatives thereof | OP BIO FACTORY CO., LTD. (JP) | 2018-10-23 | — | — | US | disclosed |
| US-10106556-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-23 | — | — | US | disclosed |
| US-20180298070-A1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-18 | — | — | US | disclosed |
| US-20180291025-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2018-10-11 | — | — | US | disclosed |
| US-10093629-B2 | Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-09 | — | — | US | disclosed |
| US-20180280389-A1 | HETEROCYCLIC COMPOUND | CARDURION PHARMACEUTICALS, LLC (US) | 2018-10-04 | — | — | US | disclosed |
| WO-2018183112-A1 | HETEROCYCLIC COMPOUND | CARDURION PHARMACEUTICALS, LLC (US) | 2018-10-04 | — | — | WO | disclosed |
| WO-2018181864-A1 | GIP RECEPTOR ACTIVATING PEPTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-04 | — | — | WO | disclosed |
| WO-2018182050-A1 | SUBSTITUTED CYCLYL-ACETIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-04 | — | — | WO | disclosed |
| WO-2018182051-A1 | IP6K INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-04 | — | — | WO | disclosed |
| US-10087150-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-02 | — | — | US | disclosed |
| US-10087229-B2 | Peptide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-02 | — | — | US | disclosed |
| EP-3105228-B1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DIABETES AND OBESITY | TAKEDA PHARMACEUTICALS CO (JP) | 2018-09-26 | — | — | EP | disclosed |
| US-10081624-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-09-25 | — | — | US | disclosed |
| US-20180263967-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-09-20 | — | — | US | disclosed |
| EP-3366684-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-08-29 | — | — | EP | disclosed |
| EP-3366679-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-08-29 | — | — | EP | disclosed |
| US-20180237404-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-23 | — | — | US | disclosed |
| US-10053468-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-21 | — | — | US | disclosed |
| US-10053456-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-21 | — | — | US | disclosed |
| US-20180222896-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-09 | — | — | US | disclosed |
| US-20180215754-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-02 | — | — | US | disclosed |
| US-10023574-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-07-17 | — | — | US | disclosed |
| US-10023544-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-17 | — | — | US | disclosed |
| US-10017487-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| EP-3342772-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-07-04 | — | — | EP | disclosed |
| WO-2018115319-A2 | INHIBITORS OF CYTOCHROME P450 FAMILY 7 SUBFAMILY B MEMBER 1 (CYP7B1) FOR USE IN TREATING DISEASES | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2018-06-28 | — | — | WO | disclosed |
| US-20180170874-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-21 | — | — | US | disclosed |
| US-10000488-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20180162853-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180162850-A1 | 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180155333-A1 | Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| WO-2018100558-A2 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | WO | disclosed |
| US-9988396-B2 | Oxaziridine compound and production method thereof | SEED RESEARCH INSTITUTE CO., LTD. (JP) | 2018-06-05 | — | — | US | disclosed |
| US-20180148446-A1 | PYRROLO [2,3-c] PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | TAKEDA PHARMACEUTICALS CO (JP) | 2018-05-31 | — | — | US | disclosed |
| EP-3327019-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-3325475-A1 | OXADIAZOLE DERIVATIVES USEFUL AS HDAC INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-3325490-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-9975903-B2 | Condensed heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9969705-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-15 | — | — | US | disclosed |
| US-9963443-B2 | Radiolabeled compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-08 | — | — | US | disclosed |
| US-20180118708-A1 | CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| EP-3313836-A1 | 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2018-05-02 | — | — | EP | disclosed |
| US-9957251-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| US-9944596-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| WO-2018065607-A1 | CHEMICAL SUBSTANCES WHICH INHIBIT THE ENZYMATIC ACTIVITY OF HUMAN KALLIKREIN RELATED PEPTIDASE 6 (KLK6) | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2018-04-12 | — | — | WO | disclosed |
| EP-3305781-A1 | CHEMICAL SUBSTANCES WHICH INHIBIT THE ENZYMATIC ACTIVITY OF HUMAN KALLIKREIN-RELATED PEPTIDASE 6 (KLK6) | Deutsches Krebsforschungszentrum (DE) | 2018-04-11 | — | — | EP | disclosed |
| EP-3031799-B1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-20180079756-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| US-20180079741-A1 | PROCESS FOR PRODUCING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-3296296-A1 | CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-03-21 | — | — | EP | disclosed |
| EP-3294706-A1 | CYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2018-03-21 | — | — | EP | disclosed |
| US-9920047-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-20 | — | — | US | disclosed |
| US-20180072694-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20180065982-A1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2018-03-08 | — | — | US | disclosed |
| US-20180057495-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-01 | — | — | US | disclosed |
| EP-3287454-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-28 | — | — | EP | disclosed |
| EP-3287441-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-28 | — | — | EP | disclosed |
| US-20180050996-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-02-22 | — | — | US | disclosed |
| US-20180044472-A1 | PRODUCTION METHOD FOR POLY(AMINO ACID) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-15 | — | — | US | disclosed |
| WO-2018030550-A1 | HETEROCYCLIC COMPOUNDS WITH AN ROR(GAMMA)T MODULATING ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-15 | — | — | WO | disclosed |
| US-9890145-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-13 | — | — | US | disclosed |
| US-20180037555-A1 | METHOD FOR PRODUCING KAKEROMYCIN AND DERIVATIVES THEREOF | OP BIO FACTORY CO., LTD. (JP) | 2018-02-08 | — | — | US | disclosed |
| EP-3279191-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
| EP-3279183-A1 | MONOCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
| EP-3275874-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-9878989-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-01-30 | — | — | US | disclosed |
| US-9878981-B2 | Method for producing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-01-30 | — | — | US | disclosed |
| EP-3266454-A1 | ACC INHIBITORS FOR USE IN TREATING MYCOBACTERIAL DISEASES | Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften (DE) | 2018-01-10 | — | — | EP | disclosed |
| US-20180002322-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-01-04 | — | — | US | disclosed |
| US-20180000780-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-04 | — | — | US | disclosed |
| EP-3263572-A1 | METHOD FOR PRODUCING KAKEROMYCIN AND DERIVATIVES THEREOF | SEED RESEARCH INSTITUTE CO., LTD. (JP) | 2018-01-03 | — | — | EP | disclosed |
| US-20170362223-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170349605-A1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-07 | — | — | US | disclosed |
| WO-2017207556-A2 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | Technische Universität München (DE) | 2017-12-07 | — | — | WO | disclosed |
| US-9834520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-05 | — | — | US | disclosed |
| US-9828357-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-28 | — | — | US | disclosed |
| WO-2017194734-A1 | MEANS AND METHODS FOR TREATING MYCOBACTERIAL DISEASES | Technische Universität München (DE) | 2017-11-16 | — | — | WO | disclosed |
| US-20170327513-A1 | OXAZIRIDINE COMPOUND AND PRODUCTION METHOD THEREOF | SEED RESEARCH INSTITUTE CO., LTD. (JP) | 2017-11-16 | — | — | US | disclosed |
| EP-3243825-A1 | OXAZIRIDINE COMPOUND AND PRODUCTION METHOD THEREOF | Seed Research Institut Co., Ltd. (JP) | 2017-11-15 | — | — | EP | disclosed |
| US-9815938-B2 | Production method for poly(amino acid) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-14 | — | — | US | disclosed |
| US-9809569-B2 | Process for producing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-07 | — | — | US | disclosed |
| WO-2017186855-A1 | UNUSUAL SUBSTRATES OF TUBULIN TYROSINE LIGASE | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2017-11-02 | — | — | WO | disclosed |
| EP-3239150-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-11-01 | — | — | EP | disclosed |
| EP-3239142-A1 | CONDENSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-9802956-B2 | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MUNCHEN-DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2017-10-31 | — | — | US | disclosed |
| US-9789083-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-17 | — | — | US | disclosed |
| US-9789084-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-17 | — | — | US | disclosed |
| WO-2017171100-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-05 | — | — | WO | disclosed |
| US-20170283406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-05 | — | — | US | disclosed |
| EP-3225618-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-10-04 | — | — | EP | disclosed |
| US-9775827-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| US-9776962-B2 | Aromatic compounds with GPR40 agonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| US-20170266162-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-09-21 | — | — | US | disclosed |
| US-20170258764-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-09-14 | — | — | US | disclosed |
| US-20170253591-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-07 | — | — | US | disclosed |
| US-9751878-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| US-9751885-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| EP-3210973-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-30 | — | — | EP | disclosed |
| EP-3210971-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-9745325-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-29 | — | — | US | disclosed |
| US-20170233339-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-17 | — | — | US | disclosed |
| EP-3205645-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-16 | — | — | EP | disclosed |
| WO-2017135306-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-10 | — | — | WO | disclosed |
| US-20170226137-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-10 | — | — | US | disclosed |
| US-20170216255-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-08-03 | — | — | US | disclosed |
| US-9718814-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-01 | — | — | US | disclosed |
| US-9718811-B2 | (S)-enantiomer of mepazine | Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2017-08-01 | — | — | US | disclosed |
| US-9714241-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-25 | — | — | US | disclosed |
| EP-3192791-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-20170197903-A1 | CATIONIC LIPID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-13 | — | — | US | disclosed |
| EP-3187497-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-07-05 | — | — | EP | disclosed |
| US-9682925-B2 | Cyclopropaneamine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-20 | — | — | US | disclosed |
| EP-3178807-A1 | CATIONIC LIPID | Takeda Pharmaceutical Company Limited (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-9675597-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-13 | — | — | US | disclosed |
| US-9662316-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-30 | — | — | US | disclosed |
| US-20170144973-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | Takenda Pharmaceutical Company Limited (JP) | 2017-05-25 | — | — | US | disclosed |
| US-9655881-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9650343-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-16 | — | — | US | disclosed |
| EP-3164388-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2017-05-10 | — | — | EP | disclosed |
| US-20170121286-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-04 | — | — | US | disclosed |
| US-20170121308-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-04 | — | — | US | disclosed |
| US-20170114042-A1 | RADIOLABELED COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-27 | — | — | US | disclosed |
| US-9630924-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-25 | — | — | US | disclosed |
| US-20170107240-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-20 | — | — | US | disclosed |
| EP-3156397-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-9624170-B2 | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (MAGL) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-18 | — | — | US | disclosed |
| US-20170100373-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-04-13 | — | — | US | disclosed |
| US-20170100384-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-04-13 | — | — | US | disclosed |
| EP-3152198-A1 | RADIOLABELED COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2017-04-12 | — | — | EP | disclosed |
| US-20170096422-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-06 | — | — | US | disclosed |
| US-9611244-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-04 | — | — | US | disclosed |
| US-20170081305-A1 | PROCESS FOR PRODUCING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-23 | — | — | US | disclosed |
| US-20170081329-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2017-03-23 | — | — | US | disclosed |
| US-20170081332-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-23 | — | — | US | disclosed |
| EP-3144308-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-03-22 | — | — | EP | disclosed |
| US-20170066737-A1 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
| WO-2017038909-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | WO | disclosed |
| EP-3134386-A1 | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | Takeda Pharmaceutical Company Limited (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-23 | — | — | US | disclosed |
| EP-3133075-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-02-22 | — | — | EP | disclosed |
| US-9573903-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-21 | — | — | US | disclosed |
| WO-2017026538-A1 | PRODUCTION METHOD OF PYRAZINE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-16 | — | — | WO | disclosed |
| US-20170044132-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-16 | — | — | US | disclosed |
| EP-3129369-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2017-02-15 | — | — | EP | disclosed |
| EP-3130581-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-20170037057-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
| US-20170027921-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-02-02 | — | — | US | disclosed |
| US-20170029417-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-02 | — | — | US | disclosed |
| EP-3124487-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-02-01 | — | — | EP | disclosed |
| US-9556175-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-01-31 | — | — | US | disclosed |
| US-9556200-B2 | Tricyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-31 | — | — | US | disclosed |
| WO-2017014323-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-26 | — | — | WO | disclosed |
| WO-2017014321-A1 | OXADIAZOLE DERIVATIVES USEFUL AS HDAC INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-26 | — | — | WO | disclosed |
| US-20170015654-A1 | PYRIDAZINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-19 | — | — | US | disclosed |
| US-20170015655-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-19 | — | — | US | disclosed |
| EP-3118192-A1 | PROCESS FOR PRODUCING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-01-18 | — | — | EP | disclosed |
| EP-3118200-A1 | PYRIDAZINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-01-18 | — | — | EP | disclosed |
| US-20170001994-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-05 | — | — | US | disclosed |
| US-9533966-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-03 | — | — | US | disclosed |
| WO-2016208775-A1 | 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-29 | — | — | WO | disclosed |
| US-20160376244-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-29 | — | — | US | disclosed |
| US-9527841-B2 | Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| EP-3105228-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-12-21 | — | — | EP | disclosed |
| EP-3105213-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-12-21 | — | — | EP | disclosed |
| WO-2016199943-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-15 | — | — | WO | disclosed |
| US-9518042-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-13 | — | — | US | disclosed |
| US-20160355494-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-08 | — | — | US | disclosed |
| US-20160347724-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-01 | — | — | US | disclosed |
| US-9499516-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-22 | — | — | US | disclosed |
| WO-2016182036-A1 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-17 | — | — | WO | disclosed |
| US-20160326102-A1 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-10 | — | — | US | disclosed |
| US-20160326133-A1 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-10 | — | — | US | disclosed |
| US-9487511-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160318864-A1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-03 | — | — | US | disclosed |
| EP-3087067-A1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2016-11-02 | — | — | EP | disclosed |
| US-20160311814-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2016-10-27 | — | — | US | disclosed |
| US-20160311811-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-27 | — | — | US | disclosed |
| US-20160311808-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2016-10-27 | — | — | US | disclosed |
| US-20160264536-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-3066094-A1 | PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS | Takeda Pharmaceutical Company Limited (JP) | 2016-09-14 | — | — | EP | disclosed |
| EP-3063139-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-09-07 | — | — | EP | disclosed |
| EP-3061754-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-08-31 | — | — | EP | disclosed |
| US-9428470-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-30 | — | — | US | disclosed |
| US-20160237087-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-18 | — | — | US | disclosed |
| EP-3055309-A1 | ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | Takeda Pharmaceutical Company Limited (JP) | 2016-08-17 | — | — | EP | disclosed |
| US-20160229814-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160222025-A1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | HELMHOLTZ ZENTRUM MUNCHEN (DE) | 2016-08-04 | — | — | US | disclosed |
| US-20160194327-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2016-07-07 | — | — | US | disclosed |
| US-20160177032-A1 | PRODUCTION METHOD FOR POLY(AMINO ACID) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20160176822-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20160176873-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20160176872-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-23 | — | — | US | disclosed |
| EP-3031799-A1 | AROMATIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-15 | — | — | EP | disclosed |
| US-9365520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| US-20160159808-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| WO-2016088903-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | WO | disclosed |
| EP-3029031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
| US-20160152598-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-02 | — | — | US | disclosed |
| US-20160152603-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-02 | — | — | US | disclosed |
| EP-3026051-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-01 | — | — | EP | disclosed |
| US-9353108-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-31 | — | — | US | disclosed |
| EP-3021847-A1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-9346776-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-24 | — | — | US | disclosed |
| US-20160137635-A1 | THE (S)-ENANTIOMER OF MEPAZINE | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2016-05-19 | — | — | US | disclosed |
| EP-3019487-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-05-18 | — | — | EP | disclosed |
| US-20160130215-A1 | CYCLOPROPANEAMINE COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-05-12 | — | — | US | disclosed |
| EP-3018126-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-3018123-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-3015488-A1 | PRODUCTION METHOD FOR POLYAMINO ACID | Takeda Pharmaceutical Company Limited (JP) | 2016-05-04 | — | — | EP | disclosed |
| EP-3013818-A1 | THE (S)-ENANTIOMER OF MEPAZINE | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2016-05-04 | — | — | EP | disclosed |
| US-20160115128-A1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-28 | — | — | US | disclosed |
| US-9321757-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-26 | — | — | US | disclosed |
| US-9321791-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-26 | — | — | US | disclosed |
| US-9315458-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2016-04-19 | — | — | US | disclosed |
| EP-3004155-A1 | PEPTIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-9278931-B2 | Cyclopropaneamine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-08 | — | — | US | disclosed |
| US-20160052988-A1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-25 | — | — | US | disclosed |
| WO-2016021742-A1 | HETEROCYCLIC COMPOUNDS AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-11 | — | — | WO | disclosed |
| EP-2975031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-01-20 | — | — | EP | disclosed |
| WO-2016002968-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-07 | — | — | WO | disclosed |
| US-20160002169-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-07 | — | — | US | disclosed |
| WO-2015190613-A1 | RADIOLABELED COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-17 | — | — | WO | disclosed |
| US-9199963-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-01 | — | — | US | disclosed |
| US-9200051-B2 | Peptide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20150307451-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | US | disclosed |
| WO-2015163485-A1 | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | WO | disclosed |
| US-20150291577-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| WO-2015156417-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-15 | — | — | WO | disclosed |
| US-20150291627-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2015-10-15 | — | — | US | disclosed |
| US-20150266881-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| US-9120777-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-01 | — | — | US | disclosed |
| WO-2015122187-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015122188-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | WO | disclosed |
| EP-2907802-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2015-08-19 | — | — | EP | disclosed |
| US-9108964-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-18 | — | — | US | disclosed |
| US-20150225361-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225354-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
| WO-2015099196-A1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-02 | — | — | WO | disclosed |
| US-20150158863-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-11 | — | — | US | disclosed |
| EP-2873669-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-05-20 | — | — | EP | disclosed |
| WO-2015068856-A1 | PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-14 | — | — | WO | disclosed |
| US-20150133451-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-14 | — | — | US | disclosed |
| WO-2015064083-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | WO | disclosed |
| US-20150119412-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-30 | — | — | US | disclosed |
| WO-2015052910-A1 | ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-16 | — | — | WO | disclosed |
| US-20150099777-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-09 | — | — | US | disclosed |
| US-20150045351-A1 | TRICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-12 | — | — | US | disclosed |
| WO-2015007730-A1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2015-01-22 | — | — | WO | disclosed |
| WO-2015005489-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-15 | — | — | WO | disclosed |
| EP-2824106-A1 | TRICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-01-14 | — | — | EP | disclosed |
| WO-2014207067-A1 | THE (S)-ENANTIOMER OF MEPAZINE | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014192284-A1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-04 | — | — | WO | disclosed |
| US-20140357552-A1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-04 | — | — | US | disclosed |
| US-20140228405-A1 | CYCLOPROPANEAMINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| EP-2743256-A1 | CYCLOPROPANEAMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-06-18 | — | — | EP | disclosed |
| WO-2014086478-A1 | INHIBITORS OF MALT1 PROTEASE | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2014-06-12 | — | — | WO | disclosed |
| US-20140128604-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-08 | — | — | US | disclosed |
| US-8664232-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2014-03-04 | — | — | US | disclosed |
| US-20120208831-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2012-08-16 | — | — | US | disclosed |
| US-8178541-B2 | For therapy of type I and type 11 diabetes mellitus, arthritis, obesity, or calcitonin-induced osteoporosis, allograft transplantation | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2012-05-15 | — | — | US | disclosed |
| US-8119648-B2 | Arthritis, obesity, (non-insulin dependent) diabetes calcitonin-induced osteoporosis; administering allograft transplantation; dipeptidyl peptidase-IV (DPP-IV) inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8034941-B2 | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-11 | — | — | US | disclosed |
| EP-1787991-B1 | PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | TAKEDA PHARMACEUTICAL (JP) | 2011-10-05 | — | — | EP | disclosed |
| EP-2308878-A2 | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and use as medicaments | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-04-13 | — | — | EP | disclosed |
| EP-2228375-A1 | New xanthin derivatives, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2010-09-15 | — | — | EP | disclosed |
| US-20100144703-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-10 | — | — | US | disclosed |
| US-7696212-B2 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG (DE) | 2010-04-13 | — | — | US | disclosed |
| US-7608627-B2 | I kappa B kinase inhibition; diabetes; (7-Chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)methanol; N-Benzyl-7-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-27 | — | — | US | disclosed |
| US-20090258856-A1 | IMIDAZOPYRIDAZINONE AND IMIDAZOPYRIDONE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
| US-7601868-B2 | Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-13 | — | — | US | disclosed |
| US-7566707-B2 | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-28 | — | — | US | disclosed |
| EP-2070539-A1 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-06-17 | — | — | EP | disclosed |
| EP-2060573-A2 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-05-20 | — | — | EP | disclosed |
| EP-2058311-A2 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-05-13 | — | — | EP | disclosed |
| US-20090093457-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-09 | — | — | US | disclosed |
| US-7482337-B2 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-01-27 | — | — | US | disclosed |
| US-20080255159-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080249089-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2008-10-09 | — | — | US | disclosed |
| US-7407955-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-08-05 | — | — | US | disclosed |
| US-20080064715-A1 | 6-Azaindole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-13 | — | — | US | disclosed |
| EP-1641799-B1 | IMIDAZO-PYRIDAZINONE DERIVATIVES AND IMIDAZO-PYRIDONE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2008-03-12 | — | — | EP | disclosed |
| US-20070293532-A1 | Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use | TAKEDA PHARMACEUTICAL COMPAN6Y LIMITED (JP) | 2007-12-20 | — | — | US | disclosed |
| EP-1787991-A1 | PYRROLOÝ2,3-c¨PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2007-05-23 | — | — | EP | disclosed |
| US-7183415-B2 | Quinoline compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) | 2006-10-05 | — | — | US | disclosed |
| US-20060128690-A1 | Amine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1593667-A1 | AMINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
| US-20050245571-A1 | Amine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050209213-A1 | Quinoline compound | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1562898-A1 | INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-20050026921-A1 | New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
| EP-1447402-A1 | QUINOLINE COMPOUND | Takeda Chemical Industries, Ltd. (JP) | 2004-08-18 | — | — | EP | disclosed |
| US-20040138214-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | US | disclosed |
| EP-1437351-A1 | AMINE DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
| WO-2004046107-A1 | INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-03 | — | — | WO | disclosed |
| US-20040097510-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-20 | — | — | US | disclosed |
| US-20040097510-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | KDM4E 3337/4885GPR3 1277/4885BCHE 3011/4885 |
| US-10787462-B2 | Heterocyclic compound | RIPK1, RIPK4, RIPK3 | KDM4E 2413/4885GPR3 1881/4885BCHE 4625/4885 |
| US-20200163970-A1 | HETEROCYCLIC COMPOUND | SQSTM1, BECN1, ATG7 | KDM4E 3374/4885GPR3 2915/4885BCHE 4766/4885 |
| US-20170121286-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | REN, AGT, AGTR1 | KDM4E 3110/4885GPR3 4193/4885BCHE 631/4885 |
| US-20190040010-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, CNR2 | KDM4E 706/4885GPR3 102/4885BCHE 1005/4885 |
| US-20200140505-A1 | PEPTIDE COMPOUND | GIPR, GLP1R, GRPR | KDM4E 4844/4885GPR3 215/4885BCHE 4106/4885 |
| US-11986480-B2 | Heterocyclic compound | SQSTM1, BECN1, ATG7 | KDM4E 3374/4885GPR3 2915/4885BCHE 4766/4885 |
| US-10189785-B2 | Heterocyclic compound | SPTLC1, SPTLC2, NPC1 | KDM4E 3051/4885GPR3 2087/4885BCHE 1211/4885 |
| US-20230149560-A1 | LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF | STING1, CGAS, TLR9 | KDM4E 3466/4885GPR3 416/4885BCHE 3894/4885 |
| US-20160152598-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | KDM4E 1279/4885GPR3 249/4885BCHE 162/4885 |
| US-20190315735-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | KDM4E 14/4885GPR3 3815/4885BCHE 1035/4885 |
| US-20040138214-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP7, DPP3 | KDM4E 1424/4885GPR3 1690/4885BCHE 872/4885 |
| US-20160311811-A1 | HETEROCYCLIC COMPOUND | IRAK4, IRAK1, IRAK2 | KDM4E 125/4885GPR3 3582/4885BCHE 4505/4885 |
| US-20090258856-A1 | IMIDAZOPYRIDAZINONE AND IMIDAZOPYRIDONE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP3, DPP7 | KDM4E 229/4885GPR3 2815/4885BCHE 1092/4885 |
| US-20160311808-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | KDM4E 14/4885GPR3 3815/4885BCHE 1035/4885 |
| US-10919891-B2 | Heterocyclic compound | CASR, AGTR2, AGTR1 | KDM4E 3607/4885GPR3 141/4885BCHE 4156/4885 |
| US-10053468-B2 | Heterocyclic compound | RORC, RORB, RORA | KDM4E 925/4885GPR3 560/4885BCHE 4134/4885 |
| US-20170327513-A1 | OXAZIRIDINE COMPOUND AND PRODUCTION METHOD THEREOF | HCCS, OXA1L, HRH1 | KDM4E 2441/4885GPR3 2840/4885BCHE 465/4885 |
| US-11059780-B2 | Substituted pyrrolidine compound and use thereof | HCRTR2, HCRTR1, CRHR2 | KDM4E 523/4885GPR3 157/4885BCHE 2085/4885 |
| US-10899752-B2 | 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor | CHRM1, CHRM4, CHRM2 | KDM4E 742/4885GPR3 153/4885BCHE 220/4885 |
| US-20180155333-A1 | Heterocyclic Compound | HCRTR1, HCRTR2, OXTR | KDM4E 2226/4885GPR3 207/4885BCHE 1178/4885 |
| US-20210024512-A1 | HETEROCYCLIC COMPOUND | TNNI3, TNNT2, TNNC1 | KDM4E 834/4885GPR3 4429/4885BCHE 4819/4885 |
| US-10202383-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP8, DPP4, DPP3 | KDM4E 829/4885GPR3 499/4885BCHE 881/4885 |
| US-20180303841-A1 | HETEROCYCLIC COMPOUND | CHRM1, CHRM2, CHRM5 | KDM4E 970/4885GPR3 180/4885BCHE 144/4885 |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | KDM4E 925/4885GPR3 560/4885BCHE 4134/4885 |
| US-20160052988-A1 | PEPTIDE COMPOUND | GIPR, GLP1R, VIP | KDM4E 3559/4885GPR3 216/4885BCHE 3212/4885 |
| US-10745397-B2 | 1-Substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as EP4 receptor antagonists | PTGER4, PTGER1, PTGER3 | KDM4E 2520/4885GPR3 113/4885BCHE 3076/4885 |
| US-11230541-B2 | Heterocyclic compound | GRIN1, GRIN2A, GRIN2B | KDM4E 3433/4885GPR3 333/4885BCHE 856/4885 |
| US-20180037555-A1 | METHOD FOR PRODUCING KAKEROMYCIN AND DERIVATIVES THEREOF | ERG28, CYP51A1, NISCH | KDM4E 1479/4885GPR3 4767/4885BCHE 3283/4885 |
| US-20210015933-A1 | BIOACTIVE CARBOXYLIC ACID TYPE COMPOUND-POLYMER CONJUGATE, AND METHOD FOR MANUFACTURING THE SAME | HCAR1, HCAR2, MCCC2 | KDM4E 1836/4885GPR3 1252/4885BCHE 156/4885 |
| US-10865200-B2 | Nitrogen-containing heterocyclic compound | CHRM1, CHRM5, CHRM2 | KDM4E 1279/4885GPR3 249/4885BCHE 162/4885 |
| US-20200339577-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER3 | KDM4E 2520/4885GPR3 113/4885BCHE 3076/4885 |
| US-10093629-B2 | Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors | RORC, RORB, RORA | KDM4E 2167/4885GPR3 368/4885BCHE 4101/4885 |
| US-11186565-B2 | Aromatic compound | GLP1R, GPR119, GPR39 | KDM4E 733/4885GPR3 52/4885BCHE 3907/4885 |
| US-20200255439-A1 | HETEROCYCLIC COMPOUND | MAG, HTT, ACHE | KDM4E 3089/4885GPR3 1028/4885BCHE 920/4885 |
| US-20160152603-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | KDM4E 1279/4885GPR3 249/4885BCHE 162/4885 |
| US-10106509-B2 | Method for producing kakeromycin and derivatives thereof | ERG28, CYP51A1, NISCH | KDM4E 1479/4885GPR3 4767/4885BCHE 3283/4885 |
| US-11970483-B2 | Heterocyclic compound | SLC10A2, VIP, HRH2 | KDM4E 3101/4885GPR3 388/4885BCHE 916/4885 |
| US-20170216255-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | KDM4E 1279/4885GPR3 249/4885BCHE 162/4885 |
| US-10208046-B2 | Nitrogen-containing heterocyclic compound | CHRM1, CHRM5, CHRM2 | KDM4E 1276/4885GPR3 143/4885BCHE 161/4885 |
| US-20170197903-A1 | CATIONIC LIPID | NPC1L1, SOAT2, CETP | KDM4E 3702/4885GPR3 3808/4885BCHE 3050/4885 |
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | SSTR1, SSTR3, NPY1R | KDM4E 2069/4885GPR3 101/4885BCHE 1369/4885 |
| US-20170121308-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | KDM4E 1268/4885GPR3 284/4885BCHE 189/4885 |
| US-10618876-B2 | Method for producing kakeromycin and derivatives thereof | ERG28, CYP51A1, NISCH | KDM4E 1479/4885GPR3 4767/4885BCHE 3283/4885 |
| US-20180162853-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | KDM4E 14/4885GPR3 3815/4885BCHE 1035/4885 |
| US-20170100384-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | KDM4E 1279/4885GPR3 249/4885BCHE 162/4885 |
| US-20190216820-A1 | ANTIFUNGAL COMPOSITION | ERG28, NR2E1, NR2C2 | KDM4E 3754/4885GPR3 2929/4885BCHE 3924/4885 |
| US-20240199553-A1 | DIFLUOROMETHYLATION REACTION OF HETEROCYCLIC RING USING TETRAFLUOROETHYLENE | CYP2F1, CYP2E1, AFF1 | KDM4E 1790/4885GPR3 2561/4885BCHE 1706/4885 |
| US-20160115128-A1 | AROMATIC COMPOUND | GLP1R, GPR119, GPR39 | KDM4E 662/4885GPR3 43/4885BCHE 3582/4885 |
| US-20100144703-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP7, DPP3 | KDM4E 1177/4885GPR3 1601/4885BCHE 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.